Growth Metrics

Summit Therapeutics (SMMT) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $42000.0.

  • Summit Therapeutics' Depreciation & Amortization (CF) rose 11000.0% to $42000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $126000.0, marking a year-over-year increase of 2989.69%. This contributed to the annual value of $89000.0 for FY2024, which is 5505.05% down from last year.
  • According to the latest figures from Q3 2025, Summit Therapeutics' Depreciation & Amortization (CF) is $42000.0, which was up 11000.0% from $37000.0 recorded in Q2 2025.
  • In the past 5 years, Summit Therapeutics' Depreciation & Amortization (CF) registered a high of $99000.0 during Q2 2022, and its lowest value of $20000.0 during Q2 2024.
  • Its 5-year average for Depreciation & Amortization (CF) is $56315.8, with a median of $46000.0 in 2023.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first surged by 12571.43% in 2021, then plummeted by 7000.0% in 2024.
  • Quarter analysis of 5 years shows Summit Therapeutics' Depreciation & Amortization (CF) stood at $79000.0 in 2021, then rose by 11.39% to $88000.0 in 2022, then tumbled by 65.91% to $30000.0 in 2023, then fell by 26.67% to $22000.0 in 2024, then skyrocketed by 90.91% to $42000.0 in 2025.
  • Its last three reported values are $42000.0 in Q3 2025, $37000.0 for Q2 2025, and $25000.0 during Q1 2025.